Radicava Prolongs Survival, Small ALS Study Shows

Radicava Prolongs Survival, Small ALS Study Shows

303283

Radicava Prolongs Survival, Small ALS Study Shows

Long-term treatment with Radicava (edaravone) is generally safe and nearly doubles survival time in adults with amyotrophic lateral sclerosis (ALS), according to a small real-life study in Japan. These data add to increasing, but still limited, evidence showing the therapy prolongs the life of ALS patients and reduces the risk of death, further highlighting Radicava’s therapeutic potential in ALS. Larger studies are needed to confirm the therapy’s survival benefits in this patient population, the researchers…

You must be logged in to read/download the full post.